menu
    • menu
    [{"orgOrder":0,"company":"BDD Pharma","sponsor":"Drug Delivery International","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Radiolabeled Compound","year":"2013","type":"Inapplicable","leadProduct":"99m-Tc Diclofenac Potassium","moa":"COX-1\/COX-2","graph1":"Neurology","graph2":"Phase I","graph3":"BDD Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"BDD Pharma \/ Drug Delivery International","highestDevelopmentStatusID":"6","companyTruncated":"BDD Pharma \/ Drug Delivery International"},{"orgOrder":0,"company":"BDD Pharma","sponsor":"Drug Delivery International","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Radiolabeled Compound","year":"2016","type":"Inapplicable","leadProduct":"99m-Tc Diclofenac Potassium","moa":"COX-1\/COX-2","graph1":"Neurology","graph2":"Phase I","graph3":"BDD Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Delayed Release","sponsorNew":"BDD Pharma \/ Drug Delivery International","highestDevelopmentStatusID":"6","companyTruncated":"BDD Pharma \/ Drug Delivery International"},{"orgOrder":0,"company":"BDD Pharma","sponsor":"N4 Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"Phosphodiesterase 5A","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"BDD Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BDD Pharma \/ BDD Pharma","highestDevelopmentStatusID":"6","companyTruncated":"BDD Pharma \/ BDD Pharma"},{"orgOrder":0,"company":"BDD Pharma","sponsor":"BDD Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Buspirone Hydrochloride","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"BDD Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BDD Pharma \/ BDD Pharma","highestDevelopmentStatusID":"5","companyTruncated":"BDD Pharma \/ BDD Pharma"},{"orgOrder":0,"company":"BDD Pharma","sponsor":"AlgiPharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"OligoG CF-5\/20","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"BDD Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Powder","sponsorNew":"BDD Pharma \/ AlgiPharma","highestDevelopmentStatusID":"8","companyTruncated":"BDD Pharma \/ AlgiPharma"},{"orgOrder":0,"company":"BDD Pharma","sponsor":"Allena Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"ALLN-346","moa":"Urate","graph1":"Rheumatology","graph2":"Phase II","graph3":"BDD Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BDD Pharma \/ BDD Pharma","highestDevelopmentStatusID":"8","companyTruncated":"BDD Pharma \/ BDD Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by BDD Pharma

    Menu

    BDD Pharma

    EVENTS

    • Webinars & Exhibitions

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            BDD Pharma

                            United Kingdom arrow
                            CTAD25
                            Not Confirmed

                            BDD Pharma

                            United Kingdom arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Buspirone Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : IND Enabling

                            Recipient : Cingulate Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cingulate Announces Complete Enrollment in Human Formulation Study of CTx-2103 for the Treatment of Anxiety Di...

                            Details : CTx-2103 (Buspirone Hydrochloride) is a novel, trimodal, extended-release tablet of buspirone incorporating Cingulate’s proprietary PTR™ drug delivery platform, and is being studied for the treatment of anxiety and/or anxiety-related disorders.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 24, 2022

                            Lead Product(s) : Buspirone Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : IND Enabling

                            Recipient : Cingulate Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            BDD Pharma

                            United Kingdom arrow
                            CTAD25
                            Not Confirmed

                            BDD Pharma

                            United Kingdom arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ALLN-346

                            Therapeutic Area : Rheumatology

                            Study Phase : Phase I

                            Recipient : Allena Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Scintigraphy Study in Healthy Volunteers to Characterize the Performance of ALLN-346 Tablets

                            Details : ALLN-346 is a Enzyme drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hyperuricemia.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            December 23, 2021

                            Lead Product(s) : ALLN-346

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Phase I

                            Recipient : Allena Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            BDD Pharma

                            United Kingdom arrow
                            CTAD25
                            Not Confirmed

                            BDD Pharma

                            United Kingdom arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sildenafil Citrate

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Recipient : N4 Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmacoscintigraphic Study to Evaluate Two Sildenafil Products

                            Details : Sildenafil is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Erectile Dysfunction.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 27, 2018

                            Lead Product(s) : Sildenafil Citrate

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Recipient : N4 Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            BDD Pharma

                            United Kingdom arrow
                            CTAD25
                            Not Confirmed

                            BDD Pharma

                            United Kingdom arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 99m-Tc Diclofenac Potassium

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Drug Delivery International

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Delayed Release Diclofenac Sodium Formulation vs Voltaren®

                            Details : 99m-Tc Diclofenac Potassium is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pain.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            March 22, 2016

                            Lead Product(s) : 99m-Tc Diclofenac Potassium

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Drug Delivery International

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            BDD Pharma

                            United Kingdom arrow
                            CTAD25
                            Not Confirmed

                            BDD Pharma

                            United Kingdom arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 99m-Tc Diclofenac Potassium

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Drug Delivery International

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Investigate Delayed-release Tablets

                            Details : 99m-Tc Diclofenac Potassium is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pain.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            December 09, 2013

                            Lead Product(s) : 99m-Tc Diclofenac Potassium

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Drug Delivery International

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            BDD Pharma

                            United Kingdom arrow
                            CTAD25
                            Not Confirmed

                            BDD Pharma

                            United Kingdom arrow
                            CTAD25
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OligoG CF-5/20

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Sponsor : AlgiPharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Investigate Lung Deposition of Radiolabelled OligoG

                            Details : OligoG CF-5/20 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Cystic Fibrosis.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            November 25, 2013

                            Lead Product(s) : OligoG CF-5/20

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Sponsor : AlgiPharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth